Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSKF3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,336
Award facts
- Contract value 100% obligated
- $11,335.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $11,335.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The contract, which requires completion by January 28, 2026, was issued without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the DLA's Medical Supply Chain division, supporting Department of Defense healthcare operations with a diverse portfolio of branded and generic prescription medications, biologics, vaccines, and medical consumables. The PPV-G GEN V is part of a broader $30.3 billion acquisition strategy designed to ensure reliable pharmaceutical supply to military healthcare facilities worldwide. As an established prime vendor under this program structure with demonstrated performance across multiple therapeutic categories, DMS Pharmaceutical Group is positioned to fulfill specialized pharmaceutical requirements for the federal military medical system, with this Xolair delivery order representing one of numerous orders issued to support ongoing medical supply needs.
Quick answers
Who was awarded contract SPE2DR26FSKF3?
SPE2DR26FSKF3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FSKF3 worth?
The government has obligated $11,336 on SPE2DR26FSKF3.
Is contract SPE2DR26FSKF3 an order under another contract?
Yes. SPE2DR26FSKF3 is a delivery order under SPE2DR25D9317, an indefinite delivery contract.
Was contract SPE2DR26FSKF3 competed?
The extent of competition for SPE2DR26FSKF3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award